Skip to main content
SpringerLink
Log in
Book cover

Basic and Clinical Tumor Immunology pp 215–256Cite as

Immunocompetence in Cancer Patients

  • Chapter

Part of the book series: Cancer Treatment and Research ((CTAR,volume 14))

Abstract

One of the most popular areas of clinical investigation has been the determination of immune status of cancer patients. Almost every issue of cancer oriented journals and of clinical immunology oriented journals contains at least one article in which some immunologic parameter is defined for a population of cancer patients. Of course, such studies are not confined to malignant disease as an extraordinary volume of literature has accumulated on the measurement of the immune parameters in a whole spectrum of pathological conditions. It is not the intent of this review to catalogue all such studies. In contrast, it is our intention to critically review the usefulness and methodology for the assessment of immunocompetence in cancer patients. Therefore, we have tended to concentrate in this review on studies with reasonable numbers of patients, where appropriate statistical analysis was included, and where reproducible methodology was employed. Even so, we have undoubtedly failed to include a large number of completely respectable scientific efforts.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Reference

  1. Burnet FM: The concept of immunological surveillance. Prog Exp Tumor Res 13: 1–27, 1970

    PubMed  CAS  Google Scholar 

  2. Stutman O: Immunological surveillance and cancer. In: The handbook of cancer immunology, Waters H (ed). New York: Waters H (ed). 1981, Vol 7, pp 1–25

    Google Scholar 

  3. Transplantation Review, Moller G (ed). Stockholm, 1976. Vol 28, Immunological Surveillance

    Google Scholar 

  4. Eilber FR, Morton DL: Impaired immunologic reactivity and recurrence following cancer surgery. Cancer 25: 362–367, 1970

    PubMed  CAS  Google Scholar 

  5. Goodwin JS: OKT3, OKT4, and all that. JAMA 246: 947–948, 1981

    Google Scholar 

  6. Brown RS, Haynes HA, Foley TH, Goodwin HA, Berard CW, Carbone PP: Hodgkins disease: Immunologic, clinical and histologic features of 50 untreated patients. Ann Intern Med 67: 291–302, 1967

    PubMed  CAS  Google Scholar 

  7. Pinsky CM, EI–Domeiri A, Caron AA, Knapper WH, Oettgen HF: Delayed hypersensitivity reactions in patients with cancer. In: Recent results in cancer research, Vol 47, Mathe G, Weiner R (eds). New York: Springer-Verlag, 1974, pp 37–41

    Google Scholar 

  8. Brosman S, Elhilali M, Vescura C, Fahey J: Immune response in bladder cancer patients. J Urology 121: 162–169, 1979

    CAS  Google Scholar 

  9. Bean MA, Schellhammer PS, Herr HW, Pinsky CM, Whitmore WF: Immunocompetence of patients with transitional cell carcinoma as measured by DNCB skin tests and in vitro lymphocyte function. Natl Cancer Inst Monogr 49: 111–114, 1978

    PubMed  Google Scholar 

  10. Eilber FR, Nizze JA, Morton DL: Sequential evaluation of general immune competence in cancer patients: Correlation with clinical course. Cancer 35: 660–665, 1975

    PubMed  CAS  Google Scholar 

  11. Wells SA Jr, Burdick JF, Christiansen C, Ketcham AS, Adkins PC: Demonstration of tumor associated delayed cutaneous hypersensitivity reactions in lung cancer patients and in patients with carcinoma of the cervix. Natl Cancer Inst Monogr 37: 197–203, 1973

    PubMed  Google Scholar 

  12. Aisenberg A: Manifestations of immunological unresponsiveness in Hodgkins disease. Cancer Res 26: 1152–1160, 1966

    PubMed  CAS  Google Scholar 

  13. Kaplan HS: Role of immunological disturbance in human oncogenesis: Some facts and fancies. Br J Cancer 25: 620–634, 1971

    PubMed  CAS  Google Scholar 

  14. Bolton PM: DNCB sensitivity in cancer patients: A review based on sequential testing in 430 patients. Clin Oncol 1: 59–69, 1975

    PubMed  CAS  Google Scholar 

  15. Eltringham JR, Kaplan HS: Impaired delayed hypersensitivity responses in 154 patients with untreated Hodgkins disease. Natl Cancer Inst Monogr 36: 107–115, 1973

    PubMed  CAS  Google Scholar 

  16. Ziegler JL, Cohen MH, Morrow RH, Kyalwazi SK, Carbone PP: Immunologic studies in Burkitt’s lymphoma. Cancer 25: 734–739, 1970

    PubMed  CAS  Google Scholar 

  17. Stjernsward J, Clifford P, Svedmyr E: In: General and tumor–distinctive cellular immunological reactivity in Burkitt’s lymphoma, Burkitt DP, Wright DH (eds). Edinburgh: E and S Livingstone, Ltd, 1970, p 164

    Google Scholar 

  18. Pinsky CM, Oettgen HF, El–Domeiri A, Old LJ, Beattie EJ, Burchenal JH: Delayed hypersensitivity reactions in patients with cancer. Proceedings of the American Association for Cancer Research 12: 100, 1971

    Google Scholar 

  19. Pinsky CM, Wanebo H, Mike V, Oettgen H: Delayed cutaneous hypersensitivity reactions and prognosis in patients with cancer. Ann NY Acad Sci 276: 407–410, 1976

    PubMed  CAS  Google Scholar 

  20. Zuckerman KS, Lo Buglio AF: Phytohemagglutanin skin tests in cancer patients. Cancer 39: 2355–2361, 1977

    PubMed  CAS  Google Scholar 

  21. Morris DL, Hersh EM, Hsi BP, Gutterman JU, Marshall MM, Mavligit GM: Recall antigen delayed type hypersensitivity skin testing in melanoma and acute leukemia patients and their associates. Cancer Res 39: 219–226, 1979

    PubMed  CAS  Google Scholar 

  22. Aranha GV, McKhann CF, Simmons RL, Grage TB: Recall skin test antigens and the prognosis of stage I melanoma. J Surg Oncol 11: 13–16, 1979

    PubMed  CAS  Google Scholar 

  23. Bates SE, Suen JY, Tranum BL: Immunological skin testing and interpretation: A plea for uniformity. Cancer 43: 2306–2314, 1979

    PubMed  CAS  Google Scholar 

  24. Bernier GM: Adult hypogammaglobulinemia. Am J Med 36: 618–623, 1964

    PubMed  CAS  Google Scholar 

  25. Fahey JL: Antibodies and immunoglobulins. J Am Med Assn 194: 255–258, 1965

    CAS  Google Scholar 

  26. Barkas T, Al–Khateeb SF, Irvine WJ, Davidson NM, Roscoe P: Inhibition of antibody dependent cell mediated cytotoxicity (ADCC) as a means of detection of immune complexes in the sera of patients with thyroid disorders and bronchogenic carcinoma. Clin Exp Immunol 25: 270–279, 1976

    PubMed  CAS  Google Scholar 

  27. Hughes NR: Serum concentrations of yG, yA and yM immunoglobulins in patients with carcinoma, melanoma, and sarcoma. J Natl Cancer Inst 46: 1015–1028, 1971

    PubMed  CAS  Google Scholar 

  28. Mandel MA, Dvorak K, Decasse JJ: Salivary immunoglobulins in patients with oropharyngeal and bronchopulmonary cancer. Cancer 31: 1408–1413, 1973

    PubMed  CAS  Google Scholar 

  29. Albin RJ, Gordon MJ, Soane WA: Levels of immunoglobulins in the serum of patients with carcinoma of the prostate. Neoplasma 19: 57–60, 1972

    Google Scholar 

  30. Wara WM, Wara DW, Phillips TL, Ammann AJ: Elevated IgA in cancer of the nasopharynx. Cancer 35: 1313–1315, 1975

    PubMed  CAS  Google Scholar 

  31. Cochran AJ, Mackie RM, Grant RM, Ross CE, Connell MD, Sandilands G, Whaley K, Hoyle DE, Jackson AM: An examination of the immunology of cancer patients. Int J Cancer 18: 298–309, 1976

    PubMed  CAS  Google Scholar 

  32. Plesnicar S: Immunoglobulins in carcinoma of the uterine cervix. Acta Radiol 11: 37–47, 1972

    CAS  Google Scholar 

  33. Shaw RK, Swzed C, Boggs DR, Fahey JL, Frei E, Morrison E, Utz JP: Infection and immunity in chronic lymphocytic leukemia. Arch Inter Med 106: 467–478, 1960

    Google Scholar 

  34. Barr M, Fairley GH: Circulating antibodies in reticuloses. Lancet 1: 1305–1310, 1961

    PubMed  CAS  Google Scholar 

  35. Cone L, Uhr JW: Immunological deficiency disorders associated with chronic lymphocytic leukemia and multiple myeloma. J Clin Invest 43: 2241–2248, 1964

    PubMed  CAS  Google Scholar 

  36. Libansky J: Study of immunologic reactivity in hemoblastosis: Circulating antibody formation as a response to antigenic stimulus in leukemia, malignant lymphoma, myeloma, and myelofibrosis. Blood 25: 169–178, 1965

    PubMed  CAS  Google Scholar 

  37. Lee AKY, Rowley M, MacKay IR: Antibody–producing capacity in human cancer. Br J Cancer 24: 454–463, 1970

    PubMed  CAS  Google Scholar 

  38. Jansen HM, The TH, deGast GC, Esselink MT, Pastoor G, Orie NG: The primary immune response of patients with different stages of squamous-cell bronchial carcinoma. Thorax 33: 755–760, 1978

    PubMed  CAS  Google Scholar 

  39. Aisenberg AC, Leskowitz S: Antibody formation in Hodgkins disease. N Eng J Med 268: 1269–1272, 1963

    CAS  Google Scholar 

  40. Levin AG, Cunningham MP, Steers AK, Miller DG, Southham CM: Production of 19S and 7S antibodies by cancer patients. Clin Exp Immunol 7: 839–849, 1970

    PubMed  CAS  Google Scholar 

  41. Quaglino D, Cowling DC: Cytochemical studies on cells from chronic lymphatic leukaemia and lymphosarcoma cultured with phytohaemagglutinin. Br J Haematol 10: 358–364, 1964

    PubMed  CAS  Google Scholar 

  42. Melief CJM, Schweitzer M, Zeylemaker WP, Verhagen EH, Eijsvoogel VP: Some immunological properties of lymphoid cells from patients with acute lymphatic leukemia (ALL). Clin Exp Immunol 15: 131–143, 1973

    PubMed  CAS  Google Scholar 

  43. Mellstedt H, Holm G: In vitro studies of lymphocytes from patients with plasma cell myeloma: I. Stimulation by mitogens and cytotoxic activities. Clin Exp Immunol 15: 309–320, 1973

    PubMed  CAS  Google Scholar 

  44. Hershorn K, Schreibman RR, Bach FH, Silzbach LE: In vitro studies of lymphocytes from patients with sarcoidosis and lymphoproliferative diseases. Lancet 2: 842–843, 1964

    Google Scholar 

  45. Fauget GB: Quantitation of immunocompetence of Hodgkins disease. J Clin Invest 56: 951–957, 1975

    Google Scholar 

  46. Orita K, Miwa H, Fukuda H, Yumura M, Uchida Y, Mamnami T, Konaga E, Tanaka S: Pre-operative cell mediated immune status of gastric cancer patients. Cancer 38: 2343–2348, 1976

    PubMed  CAS  Google Scholar 

  47. Wanebo HJ, Rao B, Miyazawa N, Martini N, Middleman MP, Oettgen HF, Beattie EJ: Immune reactivity in primary carcinoma of the lung and its relation to prognosis. J Thorac Cardiovasc Surg 72: 339–347, 1976

    PubMed  CAS  Google Scholar 

  48. Goldrosen MH, Han T, Jung D, Smolev J, Holyoke ED: Impaired lymphocyte blastogenic response in patients with colon adenocarcinoma: Effects of disease and age. J Surg Oncol 9: 229–234, 1977

    PubMed  CAS  Google Scholar 

  49. Humphrey LJ, Humphrey MA, Singla O, Volenec FJ: Immunologic responsiveness of patients with cancer: Relationship to tumor type, stage and prognosis. Ann Surg 193: 574–578, 1981

    PubMed  CAS  Google Scholar 

  50. Bjorkholm M, Holm G, Mellstedt H, Johansson B, Killander D, Sunblad R, Soderberg G: Prognostic factors in Hodgkins disease. Scand J Hematol 20: 306–318, 1978

    CAS  Google Scholar 

  51. Chretien PB, Crowder WL, Gertner HR, Sample WF, Catalona WJ: Correlation of preoperative lymphocyte reactivity with the clinical course of cancer patients. Surg Gynecol Obstet 136: 380–384, 1973

    PubMed  CAS  Google Scholar 

  52. Han T, Takita H: Immunologic impairment in bronchogenic carcinoma: A study of lymphocyte responses to phytohemagglutinin. Cancer 30: 616–620, 1972

    PubMed  CAS  Google Scholar 

  53. Payne JE, Meyer JH, Macpherson JG, Nelson DS, Walls RS, Pheils MT: The value of lymphocyte transformation in carcinoma of the colon and rectum. Surg Gynecol Obstet 150: 687–693, 1980

    PubMed  CAS  Google Scholar 

  54. Ryan RE Jr, Neel HB, Ritts RE: Correlation of pre-operative immunologic test results with recurrence in patients with head and neck cancer. Otolaryngol Head Neck Surg 88: 58–63, 1980

    PubMed  Google Scholar 

  55. Adler A, Stein JA, Ben-Efraim S: Immunocompetence, immunosuppression, and human breast cancer: III. Prognostic significance of initial level of immunocompetence in early and advanced disease. Cancer 45: 2074–2083, 1980

    PubMed  CAS  Google Scholar 

  56. Roberts MM: Lymphocyte transformation in breast cancer. Br J Surg 57: 381, 1970

    PubMed  CAS  Google Scholar 

  57. Sample WF, Gertner HR, Chretien PB: Inhibition of phytohemaglutinin induced in vitro lymphocyte transformation by serum from patients with carcinoma. J Natl Cancer Inst 46: 1291–1297, 1971

    PubMed  CAS  Google Scholar 

  58. Butterworth C, Oon CJ, Westbury G, Hobbs JR: T lymphocyte response in patients with malignant melanoma. Eur J Cancer 10: 639–646, 1977

    Google Scholar 

  59. Golub SH, Rangel DM, Morton DL: In vitro assessment of immunocompetence in patients with malignant melanoma. Int J Cancer 20: 873–880, 1977

    PubMed  CAS  Google Scholar 

  60. Golub SH, O’Connell TX, Morton DL: Correlation of in vivo and in vitro assays of immunocompetence in cancer patients. Cancer Res 34: 1833–1837, 1974

    PubMed  CAS  Google Scholar 

  61. Twomey PL, Catalona WJ, Chretien PB: Cellular-immunity in cured cancer patients. Cancer 33: 435–440, 1974

    PubMed  CAS  Google Scholar 

  62. Holmes EC, Golub SH: Immunologic defects in lung cancer patients. J Thorac Cardiovasc Surg 71: 161–167, 1976

    PubMed  CAS  Google Scholar 

  63. Berlinger NT, Good RA: Concommitant immunopathology with squamous cell carcinoma of the head and neck regions. Trans Am Acad Opthalmol Otolaryngol 82: 588–594, 1976

    CAS  Google Scholar 

  64. Suciu–Foca N, Buda J, McManus J, Theim T, Reemtsma K: Impaired responsiveness of lymphocytes and serum–inhibitory factors in patients with cancer. Cancer Res 33: 2373–2377, 1973

    Google Scholar 

  65. Cannon GB, Dean JH, Herberman RB, Perlin E, Reid J, Milter C, Lang NP: Association of depressed postoperative lymphoproliferative responses to alloantigens with poor prognosis in patients with stage I lung cancer. Int J Cancer 25: 9–17, 1980

    PubMed  CAS  Google Scholar 

  66. Han T, Takita H: Impaired lymphocyte response to allogeneic cultured lymphoid cells in patients with lung cancer. N Eng J Med 286: 605–606, 1972

    CAS  Google Scholar 

  67. Catalona WJ, Tarpley JL, Potvin C, Chretien PB: Host immunocompetence in genitourinary cancer: Relation to tumor stage and prognosis. Natl Cancer Inst Monogr 49: 105–110, 1978

    PubMed  Google Scholar 

  68. Liaw KY, Chang-Chien Y, Chen YC, Deny JS: Impaired cell mediated immunity function in thyroid cancer. Cancer 46: 285–288, 1980

    PubMed  CAS  Google Scholar 

  69. Alsabti EA: In vivo and in vitro assays of immunocompetence in bronchogenic carcinoma. Oncology 36: 171–175, 1979

    PubMed  CAS  Google Scholar 

  70. Graze PR, Perlin E, Royston IL: In vitro lymphocyte dysfunction in Hodgkins disease. J Natl Cancer Inst 56: 239–243, 1976

    PubMed  CAS  Google Scholar 

  71. Teasdale C, Roux L, Whitehead RH, Bolton RM, Hughes LE: Analysis of PHA responsiveness of lymphocytes in cancer patients. Clin Oncol 2: 306, 1976

    Google Scholar 

  72. Dean JH: Application of the microculture lymphocyte proliferation assay to clinical studies. In: Immunodiagnosis of cancer, part 2, Herberman RB, Mclntire KR (eds). New York: Marcel Dekker Inc, 1979, p 738

    Google Scholar 

  73. Golub SH, Sulit HL, Morton DL: The use of viable frozen lymphocytes for studies in human tumor immunology. Transplantation 19: 195–202, 1975

    PubMed  CAS  Google Scholar 

  74. Zacharski LR, Linman JW: Lymphocytopenia: Its causes and significance. Mayo Clin Proc 46: 168–173, 1971

    PubMed  CAS  Google Scholar 

  75. Riesco A: Five year cancer cure: Relation to total amount of peripheral lymphocytes and neutrophils. Cancer 25: 135–140, 1970

    PubMed  CAS  Google Scholar 

  76. Papatestas AE, Kark AE: Peripheral lymphocyte counts in breast carcinoma: An index of immune competence. Cancer 34: 2014–2017, 1974

    PubMed  CAS  Google Scholar 

  77. Wanebo HJ, Jun M, Strong E, Oettgen HF: T cell deficiency in patients with squamous cell cancer of head and neck. Am J Surg 130: 445–449, 1975

    PubMed  CAS  Google Scholar 

  78. West WH: E-rosette formation in immunodiagnosis. In: Immunodiagnosis of cancer, Part 2, Herberman RB, Mclntire KR (eds). New York: Marcel Dekker Inc, 1979, p 725

    Google Scholar 

  79. Kerman RH, Smith R, Stefani SS: Active T–rosette forming cells in the peripheral blood of cancer patients. Cancer Res 36: 3274–3280, 1976

    PubMed  CAS  Google Scholar 

  80. Catalona WJ, Tarpley JL, Potvin C, Chretien PB: Correlations among cutaneous reactivity to DNCB, PHA-induced lymphocyte blastogenesis and peripheral blood E-rosettes. Clin Exp Immunol 19: 327–332, 1975

    PubMed  CAS  Google Scholar 

  81. Bobrove AM, Fuks S, Strober S, Kaplan HS: Quantitation of T and B Lymphocytes and cellular immune function in Hodgkins disease. Cancer 36: 169–179, 1975

    PubMed  CAS  Google Scholar 

  82. Jerrells TR, Dean JH, Herberman RB: Relationship between T lymphocyte levels and lymphoproliferative responses to mitogens and alloantigens in lung and breast cancer patients. Int J Cancer 21: 282–290, 1978

    PubMed  CAS  Google Scholar 

  83. Anthony HM, Kirk JA, Madsen KE, Mason MK, Templeman GH: E and EAC rosetting lymphocytes in patients with carcinoma of the bronchus: I. Some parameters of the test and its prognostic significance. Clin Exp Immunol 20: 29–40, 1975

    CAS  Google Scholar 

  84. Silverman NA, Alexander JC, Potvin C, Chretien PB: In vitro lymphocyte reactivity and T cell levels in patients with melanoma: Correlations with clinical and pathological stage. Surgery 79: 332–339, 1976

    PubMed  CAS  Google Scholar 

  85. Whitehead RH, Thatcher J, Teasdale C, Rogerts GP, Hughes LE: T and B lymphocytes in breast cancer: Stage relationship and abrogation of T lymphocyte depression by enzyme treatment in vitro. Lancet 1: 330–333, 1976

    PubMed  CAS  Google Scholar 

  86. Rand RJ, Jenkins DM, Bulmer R: T and B lymphocyte subpopulations in pre-invasive and invasive carcinoma of the cervix. Clin Exp Immunol 30: 421–428, 1977

    PubMed  CAS  Google Scholar 

  87. Bensa JC, Micouin C, Schaerer R, Sotto JJ, Hollard D: Quantitative study of T and B lymphocytes in Hodgkins disease. Biomedicine 26: 137–144, 1977

    PubMed  CAS  Google Scholar 

  88. Hernandez JL, Sanz ML, Crisi CD, Voltas J, Subira ML, Zornoza G, Oehling A: Lymphocyte subpopulations in colorectal cancer-postoperative evaluation. Allergy Immunopathol 6: 339–344, 1978

    CAS  Google Scholar 

  89. Dellon AL, Potvin C, Chretien PB: Thymus dependent lymphocyte levels in bronchogenic carcinoma: Correlations in histology, clinical stage, and clinical course after surgical treatment. Cancer 35: 687–694, 1975

    PubMed  CAS  Google Scholar 

  90. West WH, Sienknecht CW, Townes AS, Herberman RB: Performance of a rosette assay between lymphocytes and sheep erythrocytes at elevated temperatures to study patients with cancer and other diseases. Clin Immunol Immunopathol 5: 60–66, 1976

    PubMed  CAS  Google Scholar 

  91. Weese JL, Oldham RK, Tormey DC, Barbock AL, Morales A, Cohen MH, Alford JC, Sharb PE, Tsangaris NT, West WH, Cannon GB, Dean JH, Djeu J, McCoy JL, Herberman RB: Immunologic monitoring in carcinoma of the breast. Surg Gynecol Obstet 145: 209–218, 1977

    PubMed  CAS  Google Scholar 

  92. Wybran J, Fudenberg HH: Thymus-derived rosette-forming cells in various human disease states: Cancer, lymphoma, bacterial and viral infections, and other diseases. J Clin Invest 52: 1026–1032, 1973

    PubMed  CAS  Google Scholar 

  93. Shirakusa T, Shigematsu N, Yosida T, Saido R, Katayama N, Inokuchi K: Changes in T cell population in patients with bronchogenic carcinoma. J Thorac Cardiovasc Surg 76: 262–265, 1978

    PubMed  CAS  Google Scholar 

  94. Oldham RK, Weese JL, Herberman RB, Perlin E, Mills M, Heim W, Blom J, Green D, Reid J, Bellinger S, Law I, McCoy JL, Dean JH, Cannon GB, Djeu J: Immunologic monitoring and immunotherapy in carcinoma of the lung. Int J Cancer 18: 739–749, 1976

    Google Scholar 

  95. Bernengo MG, Capella G, Peruccio M, Zina G: Relationship between T and B lymphocyte values and prognosis in malignant melanoma. Br J Dermatol 98:655–662, 1978,

    Google Scholar 

  96. Nemoto T, Han T, Minowada J, Angkur V, Chamberlain A, Dao T: Cell mediated immune status of breast cancer patients: Evaluation by skin test, lymphocyte stimulation and counts of rosette–forming cells. J Natl Cancer Inst 53: 641–645, 1974

    PubMed  CAS  Google Scholar 

  97. Stein JA, Alder A, Shlomo BE, Moshe M: Immunocompetence, immunosuppression, and human breast cancer. Cancer 38: 1171–1187, 1976

    PubMed  CAS  Google Scholar 

  98. Moretta L, Ferrarini M, Durante ML, Mingari MC: Expression of a receptor for IgM by human T cells in vitro. Eur J Immunol 5: 565–570, 1975

    PubMed  CAS  Google Scholar 

  99. Ferrarini M, Moretta L, Abrlle R, Durante ML: Receptors for IgG molecules on human lymphocytes forming spontaneous rosettes with sheep red cells. Eur J Immunol 5: 70–77, 1975

    PubMed  CAS  Google Scholar 

  100. Moretta L, Mingari MC, Moretta A: Human T cell subpopulations in normal and pathologic conditions. Immunological Review 45: 163–193, 1979

    CAS  Google Scholar 

  101. Gupta S: Subpopulations of human T lymphocytes: XVI. Maldistribution of T cell subsets associated with abnormal locomotion of T cells in untreated adult patients with Hodgkins disease. Clin Exp Immunol 42: 186–195, 1980

    PubMed  CAS  Google Scholar 

  102. Golightly MG, Golub SH: The in vitro culture characteristics and requirements for expression of receptors for IgM on human peripheral blood lymphocytes. Clin Exp Immunol 39: 222–232, 1980

    PubMed  CAS  Google Scholar 

  103. Lauria F, Foa R, Catovsky D: Increase in T gamma lymphocytes in B cell chronic lymphocytic leukemia. Scand J Haematol 24: 187–190, 1980

    PubMed  CAS  Google Scholar 

  104. Platsoucas CD, Kamoin S. Karanas A, Clarkson BD, Good RA, Gupta S: Receptors for immunoglobulin isotype on T and B lymphocytes from patients with untreated chronic lymphocytic leukemia. Clin Exp Immunol 40: 256–263, 1980

    PubMed  CAS  Google Scholar 

  105. Umeda T, Yokoyama H, Kobayashi K, Akaza H, Niijima T: Subsets of T lymphocytes of patients with malignancies of the urogenital tract. Cell Mol Biol 25: 95–99, 1979

    CAS  Google Scholar 

  106. Kaszubowski PA, Husky G, Tung KS, Williams RC Jr: T lymphocyte subpopulations in peripheral blood and tissues of cancer patients. Cancer Res 40: 4648–4657, 1980

    PubMed  CAS  Google Scholar 

  107. Posner MR, Reinherz EL, Breard J, Nadle LM, Rosenthal DS, Schlossman SF: Lymphocyte subpopulations of peripheral blood and spleen in untreated Hodgkins disease. Cancer 48: 1170–1176, 1981

    PubMed  CAS  Google Scholar 

  108. Karavodin LM, Guiliano AE, Golub SH: T lymphocyte subsets in patients with malignant melanoma. Cancer Immunol Immunother 11: 251–254, 1981

    Google Scholar 

  109. Nelson DL, Bundy BM, Pitchon HE, Blease RM, Stober W: The effector in human peripheral blood mediating mitogen induced cellular cytotoxicity and antibody dependent cellular cytotoxicity. J Immunol 117: 1472–1481, 1976

    PubMed  CAS  Google Scholar 

  110. MacDonald HR, Bonnard GD, Sordat B, Zawodruk SA: Antibody dependent cell mediated cytotoxicity: Heterogeneity of effector cells in human peripheral blood. Scand J Immunol 4: 487–497, 1975

    PubMed  CAS  Google Scholar 

  111. Moller G, Suehag S: Specificity of lymphocyte-mediated cytotoxicity induced by in vitro antibody–coated target cells. Cell Immunol 4: 1–19, 1972

    PubMed  CAS  Google Scholar 

  112. Catalona WJ, Ratliff TL, McCool RE: Discordance among cell-mediated cytolytic mechanisms in cancerous patients: Importance of the assay system. J Immunol 122:1009–1014,

    Google Scholar 

  113. Ting A, Terasaki PI: Depressed lymphocyte mediated killing of sensitized targets in cancer patients. Cancer Res 34: 2694–2698, 1974

    PubMed  CAS  Google Scholar 

  114. McCredie JA, MacDonald HR: Antibody dependent cellular cytotoxicity in cancer patients: Lack of prognostic value. Br J Cancer 41: 880–885, 1980

    PubMed  CAS  Google Scholar 

  115. Waller CA, Gill PG, MacLennon IC: Enhancement of lymphocyte mediated cytotoxicity after tumor resection in patients with colorectal cancer. JNCI 65: 223–230, 1980

    PubMed  CAS  Google Scholar 

  116. Eremin O, Ashby J, Franks D: Killer (K) cell activity in human normal lymph node, regional tumor lymph node, and inflammatory lymph node. Int Arch Allergy Appl Immunol 54: 210–220, 1977

    PubMed  CAS  Google Scholar 

  117. Smith JB, Knowlton RP, Koons LS: Normal antibody dependent killer cell function in patients with chronic lymphocytic leukemia. JNCI 58: 1497–1499, 1977

    PubMed  CAS  Google Scholar 

  118. Kohl S, Pickering LK, Sullivan MP, Walter DL: Impaired monocyte-macrophage cytotoxicity in patients with Hodgkins disease. Clin Immunol Immunopathol 15:577–585,

    Google Scholar 

  119. Gupta S, Fernandes G: Spontaneous and antibody dependent cellular cytotoxicity by lymphocyte subpopulations in peripheral blood and spleen from adult untreated patients with Hodgkins disease. Clin Exp Immunol 45: 205–214, 1981

    PubMed  CAS  Google Scholar 

  120. Pehamberger H, Ludwig H, Potzi P, Knapp W: Increased monocyte mediated ADCC in Hodgkin disease. Br J Cancer 41: 778–781, 1980

    PubMed  CAS  Google Scholar 

  121. deVries JE, Cornain S, Rumke P: Cytotoxicity of non-T versus T lymphocytes from melanoma patients and healthy donors on short and long term cultured melanoma cells. Int J Cancer 14: 427–434, 1974

    CAS  Google Scholar 

  122. Levin AC, Massey RJ, Deinhardt F, Schauf V, Wolter Jb: Use of a 51Cr release microcytotoxicity assay for the study of lymphocytotoxicity and inhibitors of lymphocytotoxicity in human breast cancer. In: Neoplasm immunity: Theory and application, Crispen RG (ed). Chicago: ITR, 1975, pp 107–126

    Google Scholar 

  123. Peter HH, Kalden JR, Seeland P, Diehl V, Eckert G: Humoral and cellular immune reaction 4in vitro’ against allogeneic and autologous human melanoma cells. Clin Exp Immunol 20: 193–207, 1975

    PubMed  CAS  Google Scholar 

  124. Hersey P, Edwards A, Edwards J, Adams AE, Milton GW, Nelson DS: Specificity of cell mediated cytotoxicity against human melanoma lines: Evidence for non-specific killing by activated T cells. Int J Cancer 16: 173–183, 1975

    PubMed  CAS  Google Scholar 

  125. Merrill JE, Ullberg M, Jondal Mb: Influence of IgG and IgM receptor triggering on human natural killer cell cytotoxicity measured on the level of the single effector cell. Eur J Immunol 11: 536–541, 1981

    PubMed  CAS  Google Scholar 

  126. Golightly MG, D’Amore P, Golub SH: Studies on cytotoxicity generated in mixed lymphocyte reaction: III. Natural killer-like cytotoxicity mediated by human lymphocytes with receptors for IgM. Cell Immunol 70: 219–230, 1982

    PubMed  CAS  Google Scholar 

  127. Golub SH: In situ, in vitro, and systemic regulation of NK cytotoxicity. Inb: Fundamental mechanisms in human cancer immunology, Saunders JP, Daniels JC, Serrou B, Rosenfeld C, Denney CB (eds). Amsterdam: Elsevier/North-Holland, 1981, pp 477–497

    Google Scholar 

  128. Takasugi M, Ramseyer A, Takasugi J: Decline of natural non-selective cell-mediated cytotoxicity in patients with tumor progression. Cancer Res 37: 413–418, 1977

    PubMed  CAS  Google Scholar 

  129. Pross HF, Baines MG: Spontaneous human lymphocyte mediated cytotoxicity against tumor target cells: I. The effect of malignant disease. Int. J Cancer 18: 593–604, 1976

    PubMed  CAS  Google Scholar 

  130. Kadish AS, Doyle AT, Steinhaur EH, Ghossein NA: Natural cytotoxicity and interferon production in human cancer: Deficient natural killer activity and normal interferon production in patients with advanced disease. J Immunol 127: 1817–1822, 1981

    PubMed  CAS  Google Scholar 

  131. Vose BM, Vanky F, Argrov S, Klein E: Natural cytotoxicity in manb: Activity of lymph node and tumor–infiltrating lymphocytes. Eur J Immunol 7: 753–757, 1977

    Google Scholar 

  132. Behelak Y, Banerjee D, Richter M: Immunocompetent cells in patients with malignant disease: I. The lack of naturally occurring killer activity in the unfractionated circulating lymphocytes from patients with chronic lymphocytic leukemia (CLL). Cancer 38: 2274–2227, 1976

    PubMed  CAS  Google Scholar 

  133. Eremin O, Ashby J, Stephens JP: Human natural cytotoxicity in the blood and lymphoid organs of healthy donors and patients with malignant disease. Int J Cancer 21: 35–41, 1978

    PubMed  CAS  Google Scholar 

  134. Cunningham–Rundles S, Filippa A, Braun DW, Antonelli P, Ashikari H: Natural cytotoxicity of peripheral blood lymphocytes and regional lymph node cells in breast cancer in women. JNCI 67: 585–590, 1981

    Google Scholar 

  135. Hersey P, Edwards A, Milton GW, McCarthy WH: Relationship of cell mediated cytotoxicity against melanoma cells to prognosis in melanoma patients. Br J Cancer 37: 505–513, 1978

    Google Scholar 

  136. Saijo N, Shimizu E, Irimajiri N, Ozaki A, Kimura K, Takizawa T, Niitani H: Analysis of NK activity and ADCC in healthy volunteers and in patients with primary lung carcinoma and metastatic pulmonary tumors. J Cancer Reg Clin Oncol 102: 195–214, 1982

    CAS  Google Scholar 

  137. Forbes JT, Greco FA, Oldham RK: Human natural cell mediated cytotoxicity: II. Levels in neoplastic disease. Cancer Immunol Immunother 11: 147–153, 1981

    Google Scholar 

  138. Niitsuma M, Golub, SH, Edelstein R, Holmes EC: Lymphoid cells infiltrating human pulmonary tumors: Effect of intralesional BCG injection. JNCI 67: 997–1003, 1981

    PubMed  CAS  Google Scholar 

  139. Menon M, Stephani SS: Lymphocyte–mediated natural cytotoxicity in neoplasia. Oncology 35: 63–67, 1978

    PubMed  CAS  Google Scholar 

  140. Santoli D, Trichieri G, Zmjiewski CM, Koprowski H: HLA-related control of spontaneous and antibody dependent cell mediated cytotoxic activity in humans. J Immunol 117: 765–770, 1976

    PubMed  CAS  Google Scholar 

  141. Pattengale PK, Gidlund M, Nilsson K, Sundstrom C, Sallstrom J, Simonsson B, Wigzell H: Lysis of fresh human B-lymphocyte-derived leukemia cells by interferon-activated natural killer (NK) cells. Int J Cancer 29: 1–7, 1982

    PubMed  CAS  Google Scholar 

  142. Hersey P, Hobbs A, Edwards A, McCarthy WH, McGovern VJ: Relationship between natural killer cell activity and histological features of lymphocyte infiltration and partial regression of the primary tumor in melanoma patients. Cancer Res 42: 363–368, 1982

    PubMed  CAS  Google Scholar 

  143. Naor D: Suppressor cells: Permitters and promoters of malignancy? Adv Cancer Res 29: 45–125, 1979

    PubMed  CAS  Google Scholar 

  144. Broder S, Uchiyama T, Waldmann TA: Neoplasms of immunoregulatory cells. Am J Clin Pathol 72: 724–731, 1979

    PubMed  CAS  Google Scholar 

  145. Hersey P, Wotherspoon J, Reid G, Gunz FW: Hypogammaglobulinemia associated with abnormalities of both B and T lymphocytes in patients with chronic lymphatic leukaemia. Clin Exp Immunol 39: 698–707, 1980

    PubMed  CAS  Google Scholar 

  146. Kay NE: Abnormal T-cell subpopulation function in CLL: Excessive suppressor (T gamma) and deficient helper (T mu) activity with respect to B-cell proliferation. Blood 57: 418–420, 1981

    PubMed  CAS  Google Scholar 

  147. Catovsky D, Lauria F, Matutes E, Foa R, Mantovani V, Tura S, Galton DA: Increase in T gamma lymphocytes in B-cell chronic lymphocytic leukaemia: II. Correlation with clinical stage and findings in B-prolymphocytic leukaemia. Br J Haematol 47: 539–544, 1981

    PubMed  CAS  Google Scholar 

  148. Inoshita T, Whiteside TL: Imbalance of T-cell subpopulations does not result in defective helper function in chronic lymphocytic leukemia. JNCI 67: 1277–1282, 1981

    Google Scholar 

  149. Hersh EM, Patt YZ, Murphy SG, Dicke K, Zander A, Adegbite M, Goldman R: Radiosensitive, thymic hormone-sensitive peripheral blood suppressor cell activity in cancer patients. Cancer Res 40: 3134–3140, 1980

    PubMed  CAS  Google Scholar 

  150. Moroz C, Kupfer B: Suppressor cell activity of ferratin-bearing lymphocytes in patients with breast cancer. Isr J Med Sci 17: 879–881, 1981

    PubMed  CAS  Google Scholar 

  151. Werkmeister J, McCarthy W, Hersey P: Suppressor cell activity in melanoma patients: I. Relation to tumor growth and immunoglobulin levels in vivo. Int J Cancer 15: 1–9, 1981

    Google Scholar 

  152. Schulof RS, Lee BJ, Lacher MJ, Straus DJ, Clarkson BD, Good RA, Gupta S: Concanavalin A-induced suppressor cell activity in Hodgkin disease. Clin Immunol Immunopathol 16: 454–462, 1980

    PubMed  CAS  Google Scholar 

  153. Eibl M, Krepler P, Schmidmeier W, Zielinski C, Winterleitner H: Con A-induced suppressor cells in children with acute lymphoblastic leukaemia. Clin Exp Immunol 40: 586–592, 1980

    PubMed  CAS  Google Scholar 

  154. Catalona WJ, Ratcliff TL, McCool RE: Concanavalin A-activated suppressor cell activity in peripheral blood lymphocytes of urologic cancer patients. JNCI 65: 553–557, 1980

    PubMed  CAS  Google Scholar 

  155. Toge T, Yanagawa E, Nakanishi K, Yamada Y, Niimoto M, Hattori T: Concanavalin A-activated suppressor cell activity in gastric cancer patients. Gan 71: 784–789, 1980

    PubMed  CAS  Google Scholar 

  156. Werkmeister J, Phillips G, McCarthy W, Hersey P: Suppressor cell activity in melanoma patients: II. Concanavalin A-induced suppressor cells in relation to tumor growth and suppressor T-cell subsets. Int J Cancer 28: 11–15, 1981

    PubMed  CAS  Google Scholar 

  157. Vanhaelen CP, Fisher RI: Increased sensitivity of lymphocytes from patients with Hodgkin disease to concanavalin A-induced suppressor cells. J Immunol 127: 1216–1220, 1981

    PubMed  CAS  Google Scholar 

  158. Kadish AS, Tansey FA, Yu GS, Doyle AT, Bloom BR: Interferon as a mediator of human lymphocyte suppression. J Exp Med 151: 637–650, 1980

    PubMed  CAS  Google Scholar 

  159. Schulof RS, Garofalo JA, Good RA, Gupta S: Concanavalin A-induced suppressor cell activity for T-cell proliferative responses: Autologous and allogeneic suppression in aging humans. Cell Immunol 56: 80–88, 1980

    PubMed  CAS  Google Scholar 

  160. Treves AJ, Horowitz A, Biran S, Brufman G, Fuks Z: Comparison of the response to PHA and suppressor macrophage function in different age groups of cancer patients and healthy controls. Cancer 48: 2606–2611, 1981

    PubMed  CAS  Google Scholar 

  161. Fernandez LA, MacSween JM: Generation of suppressor cells by concanavalin A: A new perspective. J Immunol 125: 267–269, 1980

    PubMed  CAS  Google Scholar 

  162. Broder S, Humphrey R, Durm M, Blackman M, Meade D, Goldman C, Strober W, Waldmann T: Impaired synthesis of polyclonal (non–paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma. N Engl J Med 293: 887–892, 1975

    PubMed  CAS  Google Scholar 

  163. Goodwin JS, Messner RP, Bankhurst AD, Peake GT, Saiki JH, Williams RC: Prostaglan dinproducing suppressor cells in Hodgkins disease. N Engl J Med 297: 963–968, 1977

    PubMed  CAS  Google Scholar 

  164. Han T:Role of suppressor cells in depression of T lymphocyte proliferative response in untreated and treated Hodgkins disease. Cancer 45:2102–2108, 1980

    Google Scholar 

  165. Twomey JJ, Laughter AH, Rice L, Ford R: Spectrum of immunodeficiencies with Hodgkins disease. J Clin Invest 66: 629–637, 1980

    PubMed  CAS  Google Scholar 

  166. Fisher RI, Vanhaelen C, Bostick F: Increased sensitivity to normal adherent suppressor cells in untreated advanced Hodgkins disease. Blood 57: 830–835, 1981

    PubMed  CAS  Google Scholar 

  167. Quan PC, Burtin P: Demonstration of nonspecific suppressor cells in the peripheral lymphocytes of cancer patients. Cancer Res 38: 288–296, 1978

    PubMed  CAS  Google Scholar 

  168. Tilden AB, Balch CM: Indomethacin enhancement of immunocompetence in melanoma patients. Surgery 90: 77–84, 1981

    PubMed  CAS  Google Scholar 

  169. Han T, Takita H: Indomethacin–mediated enhancement of lymphocyte response to mitogens in healthy subjects and lung cancer patients. Cancer 46: 2416–2420, 1980

    PubMed  CAS  Google Scholar 

  170. Braun DP, Harris JE: Relationship of leukocyte numbers, immunoregulatory cell function, and phytohemagglutinin responsiveness in cancer patients. JNCI 67: 809–814, 1981

    PubMed  CAS  Google Scholar 

  171. Murray JL, Springle C, Ishmael DR, Lee ET, Longley R, Kollmorgen GM, Nordquist RL: Adherent indomethacin-sensitive suppressor cells in malignant melanoma: Correlation with clinical status. Cancer Immunol Immunother 11: 165–172, 1981

    Google Scholar 

  172. Han T, Takita H: Depression of T lymphocyte response by non–T suppressor cells in lung cancer patients: A possible prognostic value of suppressor-cell activity. Cancer 44: 2090–2098, 1979

    PubMed  CAS  Google Scholar 

  173. Mavligit GM, Raphael LS, Calvo DB 3d, Wong WL: Indomethacin-induced, monocyte dependent restoration of local graft-versus-host reaction among cells from cancer patients. JNCI 65: 317–320, 1980

    PubMed  CAS  Google Scholar 

  174. Schechter GP, Wahl LM, Oppenheim JJ: Suppressor monocytes in human disease: A review. Adv Exp Med Biol 121B: 283–298, 1979

    Google Scholar 

  175. Herr HW: Adherent suppressor cells in the blood of patients with bladder cancer. J Urol 126: 457–460, 1981

    PubMed  CAS  Google Scholar 

  176. Spina CA, Dorey F, Vescera C, Brosman S, Fahey JL: Depression of the generation of cell-mediated cytotoxicity by macrophage-like suppressor cells in bladder carcinoma patients. Cancer Res 41: 4324–4330, 1981

    PubMed  CAS  Google Scholar 

  177. Herr HW: Suppressor cells in immunodepressed bladder and prostate cancer patients. J Urol 123: 635–639, 1980

    PubMed  CAS  Google Scholar 

  178. Zigelboim J, Corey F, Parker NH, Calcatera T, Ward P, Fahey JL: Immunologic evaluation of patients with advanced head and neck cancer receiving weekly chemoimmunotherapy. Cancer 44: 117, 1979

    Google Scholar 

  179. Berlinger NT, Good RA: Suppressor cells in healthy relatives of patients with hereditary colon cancer. Cancer 45: 1112–1116, 1980

    PubMed  CAS  Google Scholar 

  180. Jerrells TR, Dean JH, Richardson GL, McCoy JL, Herberman RB: Role of suppressor cells in depression of in vitro lymphoproliferative responses of lung cancer and breast cancer patients. JNCI 61: 1001–1009, 1978

    PubMed  CAS  Google Scholar 

  181. Uchida A, Hoshino T: Clinical studies on cell–mediated immunity in patients with malignant disease: II. Suppressor cells in patients with cancer. Cancer Immunol Immunother 9: 153–158, 1980

    Google Scholar 

  182. Hubbard GW, Wanebo H, Fukuda M, Pace R: Defective suppressor cell activity in cancer patients: A defect in immune regulation. Cancer 47: 2177–2184, 1981

    PubMed  CAS  Google Scholar 

  183. Schulof RS, Bochman RS, Garofalo J A, Cirrincione C, Cunningham-Rundles S, Fernandes G, Day NK, Pinsky CM, Incefy GS, Thaler HT, Good RA, Gupta S: Multivariate analysis of T-cell functional defects and circulating serum factors in Hodgkins disease. Cancer 48: 964–973, 1981

    PubMed  CAS  Google Scholar 

  184. Bankhurst AD, Kauffman GR, Goodwin JS, Saiki JH, Saiers JH, Williams RC Jr: Suppressor leukocytes in anergic patients with solid tumors. J. Clin Lab Immunol 3: 159–163, 1980

    PubMed  CAS  Google Scholar 

  185. Fernandez LA, MacSween JM, Langley GR: Impaired T-cell responses in chronic lymphocytic leukemia: Lack of suppressor cell effect. Clin Immunol Immunopathol 18: 168–175, 1981

    PubMed  CAS  Google Scholar 

  186. Catalona WJ, Ratcliff TL, McCool RE: Concanavalin A-inducible suppressor cells in regional lymph nodes of cancer patients. Cancer Res 39: 4372–4377, 1979

    PubMed  CAS  Google Scholar 

  187. Herr HW: Suppressor cells in the pelvic lymph nodes regional to bladder cancer. J Surg Oncol 11: 289–293, 1979

    PubMed  CAS  Google Scholar 

  188. Gallery CD, Morton DL, Golub SH: Effect of BCG immunotherapy on alloantigen-induced blastogenesis and cytotoxicity of lymph node lymphocytes in patients with melanoma. Surg Forum 30: 152–154, 1979

    Google Scholar 

  189. Vose BM, Moore MB: Suppressor cell activity of lymphocytes infiltrating human lung and breast tumours. Int J Cancer 24: 579–585, 1979

    PubMed  CAS  Google Scholar 

  190. Uchida A, Micksche M: Concanavalin A-inducible suppressor cells in pleural effusions and peripheral blood of cancer patients. Cancer Immunol Immunother 10: 203–210, 1981

    Google Scholar 

  191. Moore M, Vose BM: Extra vascular natural cytotoxicity in man: Anti-K562 activity of lymph-node and tumour-infiltrating lymphocytes. Int J Cancer 27: 265–272, 1981

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Linda M. Karavodin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sidney H. Golub
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. National Cancer Institute, Frederick Cancer Research Facility, Frederick, Maryland, USA

    Ronald B. Herberman

Rights and permissions

Reprints and permissions

Copyright information

© 1983 Martinus Nijhoff Publishers, Boston

About this chapter

Cite this chapter

Karavodin, L.M., Golub, S.H. (1983). Immunocompetence in Cancer Patients. In: Herberman, R.B. (eds) Basic and Clinical Tumor Immunology. Cancer Treatment and Research, vol 14. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-3873-4_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-3873-4_6

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-3875-8

  • Online ISBN: 978-1-4613-3873-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation